Immunity to the HER-2/neu oncogenic protein.
Immunity to the HER-2/neu oncogenic protein.
复制标题
对 HER-2/neu 致癌蛋白的免疫。
DOI：
10.1002/9780470514672.ch13
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
Cheever,MA
中科院分区：
文献类型：
--
作者：
Disis,ML;Bernhard,H;Gralow,JR;Hand,SL;Emery,SR;Calenoff,E;Cheever,MA
对致癌病毒的研究发现，转化逆转录病毒含有与细胞原癌基因同源和/或来源于细胞原癌基因的癌基因。在人类中，恶性转化通常是原癌基因激活的结果。正常原癌基因可以通过多种机制（包括点突变、易位和扩增）被激活以转化原癌基因。人类癌症免疫治疗的成功策略的开发是一个深入研究的领域。开发癌症特异性免疫疗法的部分问题是缺乏定义明确的肿瘤抗原。我们的实验室专注于通过转化原癌基因表达的致癌蛋白是否可以作为免疫攻击的靶点。一些HER-2/Neu阳性乳腺癌患者对HER-2/neu蛋白存在免疫应答，没有自身免疫的临床体征，支持过表达的致癌蛋白可以在治疗中靶向而无需担心破坏性自身免疫的想法。候选细胞毒性T淋巴细胞表位的鉴定可能允许产生用于治疗的肿瘤特异性细胞毒性T淋巴细胞，并鉴定肽疫苗的潜在表位。
The study of oncogenic viruses led to the discovery that transforming retroviruses contain oncogenes homologous with and/or derived from cellular proto‐oncogenes. In humans malignant transformation is often the result of the activation of proto‐oncogenes. Normal proto‐oncogenes can be activated to transforming proto‐oncogenes by a variety of mechanisms including point mutation, translocation and amplification. Development of successful strategies for the immunotherapy of human cancers is an area of intense investigation. Part of the problem in developing cancer‐specific immunotherapy has been the lack of well‐defined tumour antigens. Our laboratory has focused on the question of whether oncogenic proteins expressed by transforming proto‐oncogenes can serve as targets for immune attack. Some patients with HER‐2/Neu‐positive breast cancer have an existent immune response to theHER‐2/neuprotein with no clinical signs of autoimmunity, supporting the idea that overexpressed oncogenic proteins can be targeted in therapy without fear of destructive autoimmunity. The identification of candidate cytotoxic T lymphocyte epitopes might allow the generation of tumoury‐specific cytotoxic T lymphocytes for use in therapy and identify potential epitopes for peptide vaccines.